<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>patax</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>510(k) Summary illumigene C. ifficile</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Identification:</td><td rowspan=1 colspan=1>Attachment 002</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>December 31, 2010</td></tr></table>

# 510(k) number:

# K110012

Submitter: Submitter's address:

# Meridian Bioscience, Inc.

3471 River Hills Drive Cincinnati, Ohio 45244 Michelle Smith (513) 271-3700

Contact: Contact number:

FEB 2 4 2011

# Device name:

illumigene® C. difficile

# Common name:

C. difficile DNA Amplification Assay

# Classification name:

C. difficile Nucleic Acids OMN, CFR Section 866.2660

# Predicate device:

K100818: illumigene® Molecular Diagnostic Test System (illumigene C. difficile DNA Amplification Assay, illumipro-10)

Model 280050, 610172

# Reference comparator:

Cytotoxic bacterial culture

# Description of the device:

l o Sseille plation si oo-iaesoheallfiatio m ol u oll eTbA ll fc

Ma prosphatis ordMages pyroosha ora prepa eeacin mixtu.T in  ac Ma prosha mpl eu r  osiv egativ basnet h transmission.

T El  n Control Kit is required for routine Quality Control.

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>l1pat eax</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>510(k uy illuen C. diffle</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Identification:</td><td rowspan=1 colspan=1>Attachment 002</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>December 31, 2010</td></tr></table>

# Intended Use:

having Clostridium difficile-associated disease (CDAD).

al . target region was selected as an intact region remaining in all known $A + B +$ and $\mathsf { A } { \mathsf { - } } \mathsf { B } { \mathsf { + } }$ toxinotypes.

point-of-care use.

# Comparison to predicated device:

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>illumigene™ C. difficile, Revised</td><td rowspan=1 colspan=1>illumigene™ C. difficile, K100818</td></tr><tr><td rowspan=1 colspan=1>Test Format</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>DNA Amplification Assay</td></tr><tr><td rowspan=1 colspan=3>Intended Use</td></tr><tr><td rowspan=1 colspan=1>DNA Amplification Technology</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Loop-Mediated Isothermal Amplification (LAMP)</td></tr><tr><td rowspan=1 colspan=1>Target Sequences Detected</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Partial DNA fragment on the Toxin A gene of thepatogenicity ocus aLc) fun in all knownstrains for toxigenic C. difficile.</td></tr><tr><td rowspan=1 colspan=1>Qualitative/Quantitative</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Qualitative</td></tr><tr><td rowspan=1 colspan=1>Screening, Diagnostic orIdentification Test</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Diagnostic</td></tr><tr><td rowspan=1 colspan=3>Specimen Types</td></tr><tr><td rowspan=1 colspan=1>Unformed Human Stool</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>Human Stool in Cary-Blair-basedMedia</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>Reagents/Components</td><td rowspan=1 colspan=1>illumigene Sample Preparation Apparatusillumigene Reaction Bufferillumigene C. difficile Assay Deviceillumigene Heat Treatment TubesSample Collection Brushes</td><td rowspan=1 colspan=1>illumigene Sample Preparation Apparatusillumigene Reaction Bufferillumigene C. difficile Assay Deviceillumigene Extraction TubesSample Collection Brushes</td></tr><tr><td rowspan=1 colspan=1>Extraction</td><td rowspan=1 colspan=1>Not Applicable.Sample preparation by heat treatment. DNAExtraction and purification not required.</td><td rowspan=1 colspan=1>Manual</td></tr><tr><td rowspan=1 colspan=1>Amplification</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Self-contained and automated</td></tr></table>

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>l pplt fearEx</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>510(k) Summary illumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Identification:</td><td rowspan=1 colspan=1>Attachment 002</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>December 31, 2010</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Comparison to predicated device:</td></tr><tr><td></td><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>illumigene™ C. difficile, Revised</td><td rowspan=1 colspan=1>illumigene™ C. difficile</td></tr><tr><td></td><td rowspan=1 colspan=1>Detection</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Self-contained and automated</td></tr><tr><td></td><td rowspan=1 colspan=1>Testing Time</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Approximately 60 minutes</td></tr><tr><td></td><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Not required</td></tr><tr><td></td><td rowspan=1 colspan=3>Controls</td></tr><tr><td></td><td rowspan=1 colspan=1>Inhibition, Assay</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Providedillumigene Sample Preparation Apparatus:Staphylococcus aureusillumigene C. difficile Assay Device: Staphylococcusaureus LAMP Primers</td></tr><tr><td></td><td rowspan=1 colspan=1>External</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Adjunct Reagentsillumigene C. difficile External Control KitCatalog 279920</td></tr><tr><td></td><td rowspan=1 colspan=1>Extraction</td><td rowspan=1 colspan=1>Not Applicable.Sample preparation, including heat treatmentmonitored by external thermometer andinterval timer. Equipment is user supplied.</td><td rowspan=1 colspan=1>User Supplied</td></tr><tr><td></td><td rowspan=1 colspan=3>Equipment</td></tr><tr><td></td><td rowspan=1 colspan=1>Instrumentation</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>illumipro-10&#x27; Automated Isothermal Amplificationand Detection System</td></tr><tr><td></td><td rowspan=1 colspan=1>General Laboratory Equipment</td><td rowspan=1 colspan=1>Micropipette 50 μL, 200 μLDry-bath with 12mm Heat Block, 95 CInterval TimerVortex MixerDigital Thermometer with Max/MinTemperature Memory</td><td rowspan=1 colspan=1>Micropipette 50 μL, 200 μLDry-bath with 12mm Heat Block, 95 CInterval TimerVortex Mixer</td></tr><tr><td></td><td rowspan=1 colspan=1>Reading Method</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>Visible Light Transmission</td></tr><tr><td></td><td rowspan=1 colspan=3>Results</td></tr><tr><td></td><td rowspan=1 colspan=1>C. difficile Toxinotypes Tested</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>0(A+/B+)II (A+/B+)V(A+/B+)VII (A-/B+)x(A-/B+)XII (A+/B+)IX/XXIII(A+/B+)</td></tr><tr><td></td><td rowspan=1 colspan=1>Results Interpretation</td><td rowspan=1 colspan=1>No Change</td><td rowspan=1 colspan=1>INVALIDPOSITIVENEGATIVE</td></tr></table>

<table><tr><td rowspan="2">Meridian</td><td colspan="2">Sl 0kpplat .ifPeoCaresExt</td></tr><tr><td>Description:</td><td>510(k) Summary illumigene C. difficile</td></tr><tr><td rowspan="2">Bioscience, Inc.</td><td>Identification:</td><td>Attachment 002</td></tr><tr><td>Date:</td><td>December 31, 2010</td></tr></table>

# Performance Comparison, Non-clinical Tests: Interference Testing (Reference K100818)

added at final concentrations of $5 \% \lor / \lor$ or greater. Dilution Controls for each sample were prepared by adding a phosphate

t i he al concentrations listBar sula $( 5 m g / m L )$ , fecal fat (equivalent to $2 . 6 5 \ m \mathbf { \theta }$ stearic plus 1.3 mg palmitic acids per mL), hemoglobin (as methemoglobin) $( 3 . 2 m g / m L )$ IgA $( 5 m g / m L )$ , Imodium $A D ^ { \infty }$ $\{ 0 . 0 0 6 6 7 ~ \mathrm { { m g / m L } \} }$ Kaopectate $( 0 . 8 7 \ m g / \ m L )$ Metronidazole $\{ 1 2 . 5 ~ \mathsf { m g / m L } \}$ mucin $( 3 . 3 3 m g / m L )$ Mylanta $\otimes$ $( 4 . 2 m g / m L )$ Pepto-Bismo $1 0$ $( 0 . 8 7 m g / m L )$ Prilosec $( 0 . 5 \ m g / \mathsf { m L } ) .$ Tagamet $( 0 . 5 m g / m L )$ , TUMS $\oplus$ EPY $( 0 . 5 m g / m L )$ , Vancomycin $\{ 1 2 . 5 ~ \mathrm { m g / m L } \}$ whte blood cells (5%V/V), whole blood $( 5 \% V / V )$ .

# Cross-reactivity Study (Reference K100818)

at concentrations of $1 . 2 \times 1 0 ^ { 8 } / m L$ (bacteria and fungi) or $1 \times 1 0 ^ { 5 . 2 9 } / \mathsf { m L } \mathsf { T C I D } _ { 5 0 } / \mathsf { m L }$ tested in triplicate.

Types 40 and 41, Coxsackievirus, Echovirus, Rotavirus.

# Performance Comparison, Clinical Tests:

C

Sancuvala  al an p wol $( 3 9 . 3 \% )$ males and 419 $( 6 0 . 1 \% )$ females. In the case of 4 $\left\{ 0 . 6 \% \right\}$ of the patients, sex was not known. The age groups of patients range from 2 years of Sensitivity was determined to be $9 5 . 2 \%$ $( 9 5 \%  C ! : 8 9 . 2 \% - 9 7 . 9 \% )$ . Overall Specificity was determined to be $9 5 . 3 \%$ $9 5 \%$ CI: $9 3 . 2 \%$ - $9 6 . 7 \% )$ Suunt tables ho vel ssy pancas wel as peanc by cic sn pant .

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>l pcatl eaEx</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>510(k) Summary illumigene C. ifficile</td></tr><tr><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>Identification:</td><td rowspan=1 colspan=1>Attachment 002</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>December 31, 2010</td></tr></table>

Table 1. Performance data (Patients 2 years of age and above)   

<table><tr><td rowspan=2 colspan=1>Cytotoxic bacterialculture</td><td rowspan=1 colspan=4>illumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid***</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>5**</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>108</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>27*</td><td rowspan=1 colspan=1>546</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>589</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>551</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>697</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>99/104</td><td rowspan=1 colspan=1>95.2%</td><td rowspan=1 colspan=2>89.2 - 97.9%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>546/573</td><td rowspan=1 colspan=1>95.3%</td><td rowspan=1 colspan=2>93.2 - 96.7%</td></tr><tr><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>645/677</td><td rowspan=1 colspan=1>95.3%</td><td rowspan=1 colspan=2>93.4 - 96.6%</td></tr><tr><td rowspan=1 colspan=1>Invalid Rate</td><td rowspan=1 colspan=1>20/697</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=2>N/A</td></tr></table>

assay for the detection of GDH.

2/5 false negative results were negative by another FDA cleared molecular assay

$( 1 . 6 \% )$ original sample.

Table 2. Performance characteristics by site (Patients 2 years of age and above)   

<table><tr><td rowspan=2 colspan=1>Site</td><td rowspan=1 colspan=3>Positive Samples</td><td rowspan=1 colspan=3>Negative Samples</td></tr><tr><td rowspan=1 colspan=1>illumigene/Cytotoxicbacterialculture</td><td rowspan=1 colspan=1>Sensitivity %</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigenelCytotoxicbacterialculture</td><td rowspan=1 colspan=1>Specificity %</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>99/104</td><td rowspan=1 colspan=1>95.2%</td><td rowspan=1 colspan=1>89.2 - 97.9%</td><td rowspan=1 colspan=1>546/573</td><td rowspan=1 colspan=1>95.3%</td><td rowspan=1 colspan=1>93.2 - 96.7%</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>4/5</td><td rowspan=1 colspan=1>80.0%</td><td rowspan=1 colspan=1>37.6-96.4%</td><td rowspan=1 colspan=1>58/60</td><td rowspan=1 colspan=1>97.6%</td><td rowspan=1 colspan=1>88.6 -99.1%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>12/12</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>75.7 - 100%</td><td rowspan=1 colspan=1>62/67</td><td rowspan=1 colspan=1>92.5%</td><td rowspan=1 colspan=1>83.7 - 96.8%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>83.9 - 100%</td><td rowspan=1 colspan=1>87/92</td><td rowspan=1 colspan=1>94.6%</td><td rowspan=1 colspan=1>87.9-97.7%</td></tr><tr><td rowspan=1 colspan=1>Site 4</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>67.6 - 100%</td><td rowspan=1 colspan=1>36/39</td><td rowspan=1 colspan=1>92.3%</td><td rowspan=1 colspan=1>79.7-97.3%</td></tr><tr><td rowspan=1 colspan=1>Site 5</td><td rowspan=1 colspan=1>55/59</td><td rowspan=1 colspan=1>93.2%</td><td rowspan=1 colspan=1>83.8 - 97.3%</td><td rowspan=1 colspan=1>303/315</td><td rowspan=1 colspan=1>96.2%</td><td rowspan=1 colspan=1>93.5 -97.8%</td></tr></table>

Saaneacuvalat  t  ual patn plp wecol1 $( 5 3 . 4 \% )$ males and 90 $( 4 6 . 6 \% )$ observed based on patient age, gender or geographical location. Overall Sensitivity was determined to be $9 3 . 3 \%$ $9 5 \%$ CI: 78.7 - $9 8 . 2 \% )$ Overall Specificity was determined to be $9 6 . 3 \% ( 9 5 \% 0 [ 1 : 9 2 . 2 \% 0 - 9 8 . 3 \% )$ .Subsequent tables show overall assay performance as well as performance by clinical site and patient age.

<table><tr><td rowspan="2">Meridian</td><td colspan="2">Sl 0Applatie iffPeoChareisEx</td></tr><tr><td>Description:</td><td>510(k) Summary illumigene C. difficile</td></tr><tr><td rowspan="2">Bioscience, Inc.</td><td>Identification:</td><td>Attachment 002</td></tr><tr><td>Date:</td><td>December 31, 2010</td></tr></table>

Table 3. Performance data (Patients less than 2 years of age)   

<table><tr><td rowspan=2 colspan=1>Cytotoxic bacterialculture</td><td rowspan=1 colspan=4>illumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Invalid***</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>2**</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>162</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>158</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>193</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>28/30</td><td rowspan=1 colspan=1>93.3%</td><td rowspan=1 colspan=2>78.7 - 98.2%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>156/162</td><td rowspan=1 colspan=1>96.3%</td><td rowspan=1 colspan=2>92.2 - 98.3%</td></tr><tr><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>184/192</td><td rowspan=1 colspan=1>95.8%</td><td rowspan=1 colspan=2>92.0 - 97.9%</td></tr><tr><td rowspan=1 colspan=1>Invalid Rate</td><td rowspan=1 colspan=1>1/193</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=2>N/A</td></tr></table>

\* EMP $3 / 6$ assay for the detection of GDH. \* \* $1 / 2$ false negative results were negative by another FDA cleared molecular assay. Invalid results were obtained for $1 / 1 9 3 \ \{ 0 . 5 \% \}$ sple tested. heinvalidobserved was categorized as n Aay Invaliindiative f proer ple

Table  Perorance characteristics by  atients less than years )   

<table><tr><td rowspan=2 colspan=1>Site</td><td rowspan=1 colspan=3>Positive Samples</td><td rowspan=1 colspan=3>Negative Samples</td></tr><tr><td rowspan=1 colspan=1>illumigene /Cytotoxicbacterialculture</td><td rowspan=1 colspan=1>Sensitivity %</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigene /Cytotoxicbacterialculture</td><td rowspan=1 colspan=1>Specificity %</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>28/30</td><td rowspan=1 colspan=1>93.3%</td><td rowspan=1 colspan=1>78.7 - 98.2%</td><td rowspan=1 colspan=1>156/162</td><td rowspan=1 colspan=1>96.3%</td><td rowspan=1 colspan=1>92.2 - 98.3%</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>67.6 - 100%</td><td rowspan=1 colspan=1>48/49</td><td rowspan=1 colspan=1>98.0%</td><td rowspan=1 colspan=1>89.3 - 99.6%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>20/22</td><td rowspan=1 colspan=1>90.9%</td><td rowspan=1 colspan=1>72.2 - 97.5%</td><td rowspan=1 colspan=1>105/109</td><td rowspan=1 colspan=1>96.3%</td><td rowspan=1 colspan=1>90.9 - 98.6%</td></tr><tr><td rowspan=1 colspan=1>Site 4</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>2/3</td><td rowspan=1 colspan=1>66.7%</td><td rowspan=1 colspan=1>20.8 - 93.9%</td></tr><tr><td rowspan=1 colspan=1>Site 5</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20.7 - 100%</td></tr></table>

Table 5. Overall results by patient age   

<table><tr><td rowspan=2 colspan=1>Patient age</td><td rowspan=1 colspan=3>Positive Samples</td><td rowspan=1 colspan=3>Negative Samples</td></tr><tr><td rowspan=1 colspan=1>illumigene IToxigenicculture</td><td rowspan=1 colspan=1>Sensitivity %</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigene IToxigenicculture</td><td rowspan=1 colspan=1>Specificity %</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>&lt; 2 years</td><td rowspan=1 colspan=1>28/30</td><td rowspan=1 colspan=1>93.3%</td><td rowspan=1 colspan=1>78.7 - 98.2%</td><td rowspan=1 colspan=1>156/162</td><td rowspan=1 colspan=1>96.3%</td><td rowspan=1 colspan=1>92.2 -98.3%</td></tr><tr><td rowspan=1 colspan=1>≥ 2 to 12 years</td><td rowspan=1 colspan=1>10/11</td><td rowspan=1 colspan=1>90.9%</td><td rowspan=1 colspan=1>62.3-98.4%</td><td rowspan=1 colspan=1>75/79</td><td rowspan=1 colspan=1>94.9%</td><td rowspan=1 colspan=1>87.7 - 98.0%</td></tr><tr><td rowspan=1 colspan=1>&gt; 12 to 21 years</td><td rowspan=1 colspan=1>5/5</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>56.6 - 100%</td><td rowspan=1 colspan=1>53/56</td><td rowspan=1 colspan=1>94.6%</td><td rowspan=1 colspan=1>85.4 - 98.2%</td></tr><tr><td rowspan=1 colspan=1>&gt;21 years</td><td rowspan=1 colspan=1>83/87</td><td rowspan=1 colspan=1>95.4%</td><td rowspan=1 colspan=1>88.8 - 98.2%</td><td rowspan=1 colspan=1>417/437</td><td rowspan=1 colspan=1>95.4%</td><td rowspan=1 colspan=1>93.0 -97.0%</td></tr><tr><td rowspan=1 colspan=1>Age Unknown</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20.7 - 100%</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20.7 - 100%</td></tr></table>

<table><tr><td rowspan="2">Meridian</td><td colspan="2">l pplt ifceohaeiExt</td></tr><tr><td>Description:</td><td>510(k) Sumary illuiene C. diffcile</td></tr><tr><td rowspan="2">Bioscience, Inc.</td><td>Identification:</td><td>Attachment 002</td></tr><tr><td>Date:</td><td>December 31, 2010</td></tr></table>

# Analytical Sensitivity (Reference K100818)

(e.g., $9 5 \%$ or $\mathtt { 1 9 / 2 0 }$ pivplicatbtaig posivens t e olowg levelemeaans:

<table><tr><td rowspan=1 colspan=1>Strain ID</td><td rowspan=1 colspan=1>Toxinotype</td><td rowspan=1 colspan=1>Phenotype</td><td rowspan=1 colspan=1>LoD/Test</td></tr><tr><td rowspan=1 colspan=1>VPI 10463</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>A+/B+</td><td rowspan=1 colspan=1>4 CFU/test</td></tr><tr><td rowspan=1 colspan=1>2007431</td><td rowspan=1 colspan=1>III (NAP1)</td><td rowspan=1 colspan=1>A+/B+</td><td rowspan=1 colspan=1>32 CFU/test</td></tr><tr><td rowspan=1 colspan=1>CF1</td><td rowspan=1 colspan=1>VIII</td><td rowspan=1 colspan=1>A-/B+</td><td rowspan=1 colspan=1>64 CFU/test</td></tr><tr><td rowspan=1 colspan=1>2006240</td><td rowspan=1 colspan=1>V (NAP7)</td><td rowspan=1 colspan=1>A+/B+</td><td rowspan=1 colspan=1>32 CFU/test</td></tr><tr><td rowspan=1 colspan=1>B18</td><td rowspan=1 colspan=1>III</td><td rowspan=1 colspan=1>A+/B+</td><td rowspan=1 colspan=1>64 CFU/test</td></tr><tr><td rowspan=1 colspan=1>2007858</td><td rowspan=1 colspan=1>IX/XXIII</td><td rowspan=1 colspan=1>A+/B+</td><td rowspan=1 colspan=1>32 CFU/test</td></tr><tr><td rowspan=1 colspan=1>8864</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1>A-/B+</td><td rowspan=1 colspan=1>64 CFU/test</td></tr></table>

0000000B J1Typ0 001 00 BI8; Type $v$ Strais2005325, 200620, 00818 2009018, 2009065, BK6; Type VItrai:3598, 00016, CF; Type X r: 88; Type XI Strains: 2007435; Type IX/XXIl Strains: 2007858 Unknown Strains: 2009132, 2009155, 2009277.

# Reproducibility (Reference K100818)

c detection $( n = 3 )$ and just below the limit of blank (i.e., high negative sample, $n = 3$ The panels also included uncharacterized positive $( n = 2 )$ and negative $( n = 2 )$ samplesetg was pe by dfent eators    n he me y -assy blity  ys nteassy vaire o ill $c$ diicile   l the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 3</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>19/19****</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>59/59</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>25/30</td><td rowspan=1 colspan=1>83%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>28/30</td><td rowspan=1 colspan=1>93%</td><td rowspan=1 colspan=1>82/90</td><td rowspan=1 colspan=1>91%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>60/60</td><td rowspan=1 colspan=1>100%</td></tr></table>

\*\*\* 1 specimen generated an instrument invalid test result.

# Conclusions

The illumigene C. difficile assay used in conjunction with the illumipro- $\$ 0$ can be used to detect toxigenic C. difficile in human stool samples from pediatric and adult patients. The test is diagnostic for toxigenic C. difficile infection.

Meridian Bioscience, Inc. c/o Ms. Michelle L. Smith Director Quality Systems 3471 River Hills Drive Cincinnati, OH 54244

# FEB 2 4 2011

Re: K110012 Trade/Device Name: illumigeneTM C. difficile DNA Amplification Assay Regulation Number: 21 CFR § 866.2660 Regulation Name: Microorganism differentiation and identification device Regulatory Class: Class I Product Codes: OMN Dated: December 31, 2010 Received: January 3, 2011

Dear Ms. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice

requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours, Saathy

Sally A. Hojvat, M.Sc., Ph.D. Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indication(s) for Use Form

510(k) Number (if known): K11ODIZ

Device Name:illumigene Molecular Diagnostic Test System (illumigene® C. difficile DNA Amplification Assay, illumipro- ${ \mathfrak { 1 0 } } ^ { \pi ^ { \mu } }$ )

# Indications for Use:

The illeC.difficileDNA plicati assy perform n he illipro1 is  qualitativn n patients suspected of having Clostridium difficile-associated disease (CDAD).

The il  oaoalpat C o Toi      s Toxin A gene. The tcdA target region was selected as an intact region remaining in all known $A + B +$ and $\mathsf { A } { \boldsymbol { \cdot } } \mathsf { B } { \boldsymbol { + } }$ toxinotypes.

intended for point-of-care use.

Prescription Use___ Over-The-Counter Use (Part 21 CFR 801 Subpart D) AND/OR (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/6b5bedfd262415703d758e47e3e7b0a1b8df1dab53bcdbaed3955f6132b89eb2.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) 12110012